CPMV Stock — Mosaic Immunoengineering Inc

Mosaic Immunoengineering Inc (CPMV)

Updated October 15, 2026.

CPMV is a Stock. Its deepest 1-year drawdown was 94.9%.

Mosaic ImmunoEngineering is a development-stage biotechnology company focused on advancing and commercializing immunotherapies for cancer treatment, building a pipeline of new product candidates and platforms. The company does not currently distribute to shareholders. This security appeals primarily to investors seeking exposure to early-stage biotech development rather than those focused on generating current income.

CPMV performance

Returns are updating. CPMV's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 94.9%.

CPMV key facts

Asset type

Stock

Asset class

Equity

Inception date

04/04/1994

Distribution frequency

None

Last close

$0.33 (as of 2026-10-15)

Market cap

$2,411,632

Average volume

0.0

Last known dates

ex 03/02/2007; payment 12/02/2020

Date quality

Unmatched ex / payment pair — not a live schedule

Beta

-0.682

Payout ratio

0.0%

Forward P/E

10.8108

EPS

$-0.10

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CPMV risks and drawbacks

The deepest 1-year drawdown on record here is 94.9%.

Who may consider CPMV — and who may not

It is a weaker fit for investors who need monthly cash flow (CPMV does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on CPMV

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions